Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.54 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.43 |
| ▸ | FGF1 | P05230 | 1/20 | 0.42 |
| ▸ | FGF2 | P09038 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2028172 | 0.97 | F2 (0.51) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL15968033 | 0.95 | F2 (0.49) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL3614161 | 0.85 | PLCD1 (0.59) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL28352827 | 0.85 | TDP1 (0.50) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL2028171 | 0.83 | PLCD1 (0.55) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL486814 | 0.83 | PLCD1 (0.56) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL486900 | 0.81 | F2 (0.53) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL22529457 | 0.81 | PLCD1 (0.54) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL25306518 | 0.80 | TDP1 (0.55) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL24590149 | 0.78 | F2 (0.66) | F2PRSS1PRSS2PRSS3TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240108585-A1 | COMPOSITIONS COMPRISING LIPID-BASED NANOPARTICLES FOR TREATING DIABETES MELLITUS | SDG, INC. | 2024-04-04 | — | — | US | claimed |
| US-20230172868-A1 | LIPID-BASED NANOPARTICLES WITH ENHANCED STABILITY | SDG, INC. (US) | 2023-06-08 | — | — | US | claimed |
| US-20210379160-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | SDG INC (US) | 2021-12-09 | — | — | US | claimed |
| US-11077173-B2 | Lipid-based nanoparticles and methods using same | SDG, INC. (US) | 2021-08-03 | — | — | US | claimed |
| US-11071715-B2 | Lipid-based nanoparticles and methods using same | SDG, INC. (US) | 2021-07-27 | — | — | US | claimed |
| US-20210137838-A1 | LIPID-BASED NANOPARTICLES WITH ENHANCED STABILITY | SDG, INC. | 2021-05-13 | — | — | US | claimed |
| US-10918700-B2 | Lipid-based nanoparticles and use of same in optimized insulin dosing regimens | SDG, INC. (US) | 2021-02-16 | — | — | US | claimed |
| US-20200375913-A1 | COMPOSITIONS COMPRISING LIPID-BASED NANOPARTICLES FOR TREATING DIABETES MELLITUS | SDG, INC. | 2020-12-03 | — | — | US | claimed |
| US-20200330560-A1 | LIPID-BASED NANOPARTICLES AND METHODS USING SAME | SDG, INC. | 2020-10-22 | — | — | US | claimed |
| US-20200323961-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | SDG, INC. (US) | 2020-10-15 | — | — | US | claimed |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2020-08-20 | — | — | US | claimed |
| US-10463616-B2 | Lipid construct for delivery of insulin to a mammal | SDG, INC. (US) | 2019-11-05 | — | — | US | claimed |
| US-20190054021-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. | 2019-02-21 | — | — | US | claimed |
| US-10004686-B2 | Lipid construct for delivery of insulin to a mammal | SDG, INC. (US) | 2018-06-26 | — | — | US | claimed |
| US-20240139288-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | SDG INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240108585-A1 | COMPOSITIONS COMPRISING LIPID-BASED NANOPARTICLES FOR TREATING DIABETES MELLITUS | SDG, INC. | 2024-04-04 | — | — | US | disclosed |
| US-20230172868-A1 | LIPID-BASED NANOPARTICLES WITH ENHANCED STABILITY | SDG, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20200330560-A1 | LIPID-BASED NANOPARTICLES AND METHODS USING SAME | SDG, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200323961-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | SDG, INC. (US) | 2020-10-15 | — | — | US | disclosed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379160-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | PNLIP, IAPP, LIPC | F2 4145/4885PRSS1 1621/4885PRSS2 2497/4885 |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | F2 2252/4885PRSS1 1301/4885PRSS2 609/4885 |
| US-20200330560-A1 | LIPID-BASED NANOPARTICLES AND METHODS USING SAME | LIPA, PLIN3, CETP | F2 4708/4885PRSS1 4144/4885PRSS2 4298/4885 |
| US-10918700-B2 | Lipid-based nanoparticles and use of same in optimized insulin dosing regimens | PNLIP, IAPP, LIPC | F2 4145/4885PRSS1 1621/4885PRSS2 2497/4885 |
| US-10004686-B2 | Lipid construct for delivery of insulin to a mammal | INSR, IAPP, GPR119 | F2 2597/4885PRSS1 3800/4885PRSS2 2963/4885 |
| US-20240108585-A1 | COMPOSITIONS COMPRISING LIPID-BASED NANOPARTICLES FOR TREATING DIABETES MELLITUS | IAPP, PNLIP, LIPC | F2 2699/4885PRSS1 2782/4885PRSS2 2468/4885 |
| US-20230172868-A1 | LIPID-BASED NANOPARTICLES WITH ENHANCED STABILITY | LIPA, NPC1L1, PLIN3 | F2 4503/4885PRSS1 3930/4885PRSS2 4022/4885 |
| US-11077173-B2 | Lipid-based nanoparticles and methods using same | LIPA, PLIN3, CETP | F2 4708/4885PRSS1 4144/4885PRSS2 4298/4885 |
| US-20190054021-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | F2 2597/4885PRSS1 3800/4885PRSS2 2963/4885 |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | F2 2597/4885PRSS1 3800/4885PRSS2 2963/4885 |
| US-20200323961-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | PNLIP, IAPP, LIPC | F2 4145/4885PRSS1 1621/4885PRSS2 2497/4885 |
| US-10463616-B2 | Lipid construct for delivery of insulin to a mammal | INSR, IAPP, GPR119 | F2 2597/4885PRSS1 3800/4885PRSS2 2963/4885 |
| US-20210137838-A1 | LIPID-BASED NANOPARTICLES WITH ENHANCED STABILITY | LIPA, NPC1L1, PLIN3 | F2 4503/4885PRSS1 3930/4885PRSS2 4022/4885 |
| US-20200375913-A1 | COMPOSITIONS COMPRISING LIPID-BASED NANOPARTICLES FOR TREATING DIABETES MELLITUS | IAPP, PNLIP, LIPC | F2 2699/4885PRSS1 2782/4885PRSS2 2468/4885 |
| US-11071715-B2 | Lipid-based nanoparticles and methods using same | LIPA, PLIN3, CETP | F2 4708/4885PRSS1 4144/4885PRSS2 4298/4885 |
| US-20240139288-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | PNLIP, IAPP, LIPC | F2 4145/4885PRSS1 1621/4885PRSS2 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.